< All Tickers
FMS
Fresenius Medical Care
Earnings
FMS | Earnings Review
Fresenius Medical Care AG | FY2026 Q1 reported May 5, 2026 | Analysis date: May 11, 2026 | Daloopa company_id 151435
Revenue (EUR B)
EUR 4.612B
4.612B reported = -5.5% YoY (FX, LatAm divestiture, VBC reset); +4% organic. First negative reported revenue print in 2 quarters
FY26 Guide
Confirmed, not raised
Revenue broadly flat; OI +/- MSD vs EUR 2.212B base. First miss/in-line after 8 consecutive beats — by design. Banking Q1 OPB to absorb H2 TDAPA reversal
'Headline weak, underlying constructive' — by design. FMS reported Q1 2026 on May 5, the first quarter of a deliberately telegraphed transition year. Reported revenue EUR 4.612B was -5.5% YoY (FX, LatAm divestiture, ~EUR 300M FY26 VBC risk-contracting reset), but organic was +4%. Operating income ex-SI EUR 467M grew +10% constant-currency / +2.2% reported; reported OI EUR 286M absorbed EUR 181M of FME25+ special items (vs EUR 126M Q1'25 — FME25+ costs ramping). EPS ex-SI EUR 0.91 +8.3% YoY (+16% cc); basic EPS EUR 0.43 -50% on FME25+ noise. Operational positives: FME25+ delivered EUR 50M of sustainable savings in Q1 (front-loaded vs EUR 250M FY26 target); 5008X/HVHDF rollout ahead of milestones (~100 US clinics, >100k treatments by early April vs target 36,000 patients across 28 states by YE); 64 of up to 100 planned US clinic closures already executed; capex/inflation tracking inside plan; EUR 1B buyback program completing ~1 year ahead of schedule (24.8M shares / 8.5% of capital); net leverage 2.5x (low end of 2.5-3.0x band). The single negative datapoint: US same-market treatment growth -37 bps (vs Q1'25 -1.1% and FY26 'carefully assume flat'). Driven by weather, missed treatments, ACA enrollment uncertainty, clinic closures, elevated mortality. FY2026 guidance confirmed, not raised: revenue broadly flat (EUR/USD 1.18 assumed), OI in +/- mid-single-digit range vs EUR 2.212B base, OI margin 10.5-12%. Q1 TDAPA contribution ~EUR 80M cc — the entire H1 vs H2 phasing dynamic. Phosphate binder TDAPA expires mid-2026; ~EUR 100M expected to persist (EUR 50M clinic + EUR 50M pharmacy). Why not raise? Mgmt is deliberately banking Q1 outperformance to absorb the H2 TDAPA reversal. Watch: (1) Q2 print Aug 2026 — phasing test before TDAPA cliff; (2) CY2027 ESRD PPS proposed rule (Jun/Jul 2026), final rule Oct/Nov — phosphate binder bundle integration; (3) ACA subsidy expiry phasing Q2-Q4; (4) HVHDF cohort maturation (mortality readout needs 2.5+ years post-3-month conversion); (5) Joe Turk as new Care Enablement CEO from Jan 1, 2026 — portfolio strategy. Thesis read: FMS Q1'26 was the first miss/in-line after 8 straight beats — but deliberate. Investment debate is no longer 'did FME25 work' (it did, EUR 804M cumulative through 2025) but 'can FME25+ + HDF + RCM bridge the H2 TDAPA cliff and set up positive growth in 2027.' Caveat: Q1'26 transcript not available via FMP; Q&A built from Quartr/StockAnalysis public notes + FY2025Q4 transcript.
Key Metrics Trends
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue (EUR B) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M |
| Revenue (EUR B) YoY % | - | - | - | - | +0.5% | +2.6% | -0.3% | -5.5% |
| Revenue YoY % | 1.3% | 0.2% | 1.1% | 3.3% | 0.5% | 2.6% | -0.3% | -5.5% |
| Revenue YoY % YoY chg (bps) | - | - | - | - | -80 | +240 | -140 | -880 |
| Op Income ex-SI (EUR M) | $490M | $545M | $575M | $457M | $476M | $574M | $705M | $467M |
| Op Income ex-SI (EUR M) YoY % | - | - | - | - | -2.9% | +5.3% | +22.6% | +2.2% |
| Op Margin ex-SI % | 10.3% | 11.4% | 11.3% | 9.4% | 9.9% | 11.8% | 13.9% | 10.1% |
| Op Margin ex-SI % YoY chg (bps) | - | - | - | - | -40 | +40 | +260 | +70 |
| EPS ex-SI (EUR) | $0.72 | $0.81 | $0.91 | $0.84 | $0.91 | $1.10 | $1.44 | $0.91 |
| EPS ex-SI (EUR) YoY % | - | - | - | - | +26.4% | +35.8% | +58.2% | +8.3% |
| EPS ex-SI YoY % | 0.0% | 0.0% | 0.0% | 31.3% | 26.4% | 35.8% | 58.2% | 8.3% |
| EPS ex-SI YoY % YoY chg (bps) | - | - | - | - | +2640 | +3580 | +5820 | -2300 |
| US Same-Market Treatment Growth % | 0.0% | 0.0% | 0.0% | -1.1% | 0.0% | -0.4% | -0.4% | -0.6% |
| US Same-Market Treatment Growth % YoY chg (bps) | - | - | - | - | +0 | -40 | -40 | +50 |
| Dialysis Clinics (count) | 0.0 | 0.0 | 0.0 | 3,674.0 | 3,676.0 | 3,628.0 | 3,601.0 | 3,539.0 |
| Dialysis Clinics (count) YoY % | - | - | - | - | - | - | - | -3.7% |
_Trajectory: top line flat-to-negative; underlying margin trajectory inflecting up; Q1'26 first headline miss after 8 straight beats — by design. Revenue YoY: +1.3% / +0.2% / +1.1% / +3.3% / +0.5% / +2.6% / -0.3% / -5.5%. EPS ex-SI YoY: turned the corner Q1'25 (+31%) → peak Q4'25 (+58%) → Q1'26 +8.3% (decel of -4,990 bps QoQ as Q4 seasonality + TDAPA fade and FME25+ specials ramp). Five inflection points: (1) FY'24 trough and FME25 lift-out — FY'24 OI EUR 1.392B was cycle low; FME25 EUR ~650M cumulative savings powered four quarters of 25-60% EPS ex-SI growth. Q4'25 was peak optical at EUR 1.44 EPS-ex-SI and EUR 705M OI ex-SI. (2) TDAPA H2'26 reversal (the cliff) — Q1'26 captured ~EUR 80M of TDAPA tailwind at cc per CFO Fischer; phosphate binder TDAPA expires mid-2026, ~EUR 100M expected to persist (EUR 50M clinic + EUR 50M pharmacy). (3) Dialysis volume normalization + GLP-1 overhang — SMTG US went from positive 2023 → -1.1% Q1'25 → -0.6% Q1'26; mortality still elevated vs pre-COVID baseline; missed treatments up; ACA enrollment uncertainty; 3,539 clinics in Q1'26 vs 3,674 in Q1'25 (135 net closures). (4) FME25+ transformation costs — EUR 181M of specials in Q1'26 (gap between reported OI EUR 286M and ex-SI EUR 467M); EUR 400M cost / EUR 400M savings program through 2027, front-loaded. (5) 5008X/HVHDF rollout — ~100 US clinics + 100K+ HDF treatments by early April; clinical differentiator vs DaVita; HVHDF mortality benefits ramp 2.5+ years post-3-month conversion → first cohort maturation visible 2027._
Beat/Miss
Guidance
Catalysts
Street Q&A
Contradictions
Read-Throughs
This Quarter vs Consensus
| Metric | Consensus (workflow-implied) | Actual | Variance | Read |
|---|---|---|---|---|
| Revenue (EUR B) | ~4.62 | 4.612 | ~-0.2% | In line / slight miss — FX + LatAm divestiture drag |
| Operating income ex-SI (EUR M) | ~455 | 467 | +12 / +2.6% | Slight beat — +10% cc |
| Reported operating income (EUR M) | n/a | 286 | n/m | Below on reported basis — EUR 181M FME25+ specials |
| Op margin ex-SI % | ~9.8% | 10.1% | +30 bps | Slight beat |
| Basic EPS (EUR) | ~0.48 | 0.43 | -0.05 | Miss on reported EPS |
| EPS ex-SI (EUR) | n/a | 0.91 | +8.3% YoY (+16% cc) | Positive optical |
| US Same-Market Treatment Growth | Flat assumed | -0.6% | -37 bps Q1 disclosure | Soft — weather + missed treatments + ACA + mortality |
| Q1 TDAPA contribution (EUR M cc) | n/a | ~80 | — | H1 tailwind that reverses H2 |
| FME25+ Q1 sustainable savings (EUR M) | Tracking EUR 250M FY | ~50 | Front-loaded | Ahead of pace |
| L12Q Revenue beat rate | — | ~83% | — | Pre-Q1'26 consistent beater |
| L12Q EPS beat rate | — | ~75% | — | Pre-Q1'26 consistent beater |
| L4Q Revenue beat rate | — | 75% | — | Q1'26 broke 8-Q streak |
| L4Q EPS beat rate | — | 75% | — | Q1'26 broke 8-Q streak |
Pattern: 'Consistent beater through FME25 ramp → deliberate Q1'26 inflection on a transition-year setup.' FMS had beaten consensus for 8 consecutive quarters through the 2024-2025 FME25 ramp. Q1'26 is the first visible miss/in-line — a CLEAN reflection of the transition-year framing introduced on the Q4'25 call, NOT operational disappointment. Constant-currency adjusted metrics (OI ex-SI +10%, adj EPS +16%) remained firmly positive. Management explanation: (1) SMTG -37 bps on weather, missed treatments, ACA uncertainty, clinic closures, elevated mortality — Giza had pre-flagged Q4'25 that 2026 assumes flat SMTG with 'normal flu season'; (2) GLP-1 noise NOT cited as in-quarter driver — mgmt re-iterated GLP-1 ESRD cohort as a TAILWIND to the 2%+ path; (3) FME25+ EUR 50M Q1 savings front-loaded vs EUR 250M FY target, but EUR 181M specials suppressed reported OI; (4) TDAPA Q1 ~EUR 80M cc — single biggest reason consensus EPS came above reported (H1 tailwind reverses H2); (5) VBC ~EUR 300M FY revenue headwind from risk-contracting reset flowing through Q1; (6) HDF ahead of pace — ~100 clinics, >100K treatments by early April; (7) FX at 1.18 EUR/USD assumed in plan.
Guidance Deep Dive
| Metric (FY2026) | Prior Guide (Q4'25) | Q1'26 Update | Read | Source |
|---|---|---|---|---|
| Revenue | Broadly flat vs FY25 (EUR/USD 1.18) | Confirmed | Organic +LSD, offset by VBC ~EUR 300M, divestitures -30 bps, FX | — |
| Operating income ex-SI | +/- MSD% vs FY25 base EUR 2.212B | Confirmed | H1 positive, H2 negative as TDAPA rolls off | — |
| OI margin % | Implied 10.5-12.0% | Confirmed | Maintains FME25 10-14% transformation band | — |
| FME25+ incremental savings | EUR 250M FY26 | Confirmed; EUR 50M delivered Q1 | Ahead of pace; FY26 onetime costs ~EUR 350M | src |
| FME25+ cumulative savings target | EUR 1.2B by end-2027 (EUR 804M through 2025) | Confirmed | EUR 400M combined incremental '26+'27 | — |
| Regulatory effects (headwind) | EUR 150M-200M (binder TDAPA + ACA) | Confirmed | Binder TDAPA ~EUR 100M+ + ACA ~EUR 50M | src |
| Strategic investments | EUR 100M-150M (5008X/HDF + SAP S/4HANA) | Confirmed | IT ~half of total | src |
| Business growth (ex-reg/invest) | EUR 250M-350M | Confirmed | Pricing, rate/mix, RCM | src |
| Inflation headwind | EUR 200M-300M | Confirmed; tracking within | Slight de-risking | — |
| Corporate costs | EUR 200M-220M | Confirmed | SAP S/4HANA driving step-up | — |
| Effective tax rate | 22-24% | Confirmed | — | — |
| FY2026 raise? | — | NO — confirmed only | Deliberately banking Q1 outperformance to absorb H2 TDAPA reversal | — |
Tone: cautious-confirm. Hair more confident on execution (HDF, FME25+, inflation), equally cautious on SMTG and TDAPA H2 reversal. Q4'25 call (Feb 2026) introduced the 2026 outlook as a 'transition year' — Helen Giza used the word 'careful' twice on SMTG. Q1'26 confirmed the framing. The decision to confirm rather than raise — despite +10% cc OI ex-SI growth — is the signal: mgmt wants H2 visibility before committing. Verbatim risk caveats: (1) GLP-1 impact 'longer-arc factor'; risk that GLP-1 reduces ESRD incidence faster than mortality improvements lift prevalent population. (2) US ESRD dynamics: 'elevated missed treatments,' 'elevated mortality,' 'ACA enrollment uncertainty,' 'clinic closures' all cited as Q1 SMTG drivers; mortality data 'needs more time.' (3) FX: outlook based on EUR/USD 1.18; Q1 already showed translational pressure. (4) FME25+ execution: onetime costs front-loaded into 2026 (~EUR 350M), savings back-loaded into 2027; ~100 clinic closures + real estate + SAP S/4HANA = real disruption risk. (5) TDAPA-to-bundle transition: 'we don't know what that bundle payment will be in 2027 yet' (Q4'25). (6) China: 7-10% of Care Enablement; EUR 50M EBIT drag 2025, lower but persistent 2026; portfolio under review (Joe Turk new CE CEO Jan 1, 2026). (7) ACA: ~EUR 50M sized 2026; mgmt declined to quantify 2027-28 step. FY27 implied trajectory: 3-7% OI CAGR aspiration to 2028, low-teens if you strip out TDAPA tail + ACA. Drivers: FME25+ savings flow cleaner, HVHDF cohort benefits begin landing, VBC inflects positive, residual TDAPA-to-bundle erosion partial offset. Upper end of 3-7% achievable if execution holds.
Upcoming Catalysts
| # | Catalyst | Timing | Consensus View / Read | Risk/Reward |
|---|---|---|---|---|
| 1 | CY2027 ESRD PPS rulemaking — phosphate binder bundle integration | Proposed rule Jun/Jul 2026; final rule Oct/Nov 2026 | CY2026 final rule delivered 2.2% rate increase; bundle integration determines residual ~EUR 100M binder economics post-mid-2026 TDAPA expiry | Risk: pass-through rate well below TDAPA economics compresses 2027-28 bridge. Reward: orderly transition with dispensing add-on precedent |
| 2 | Q2 2026 earnings print | Early August 2026 | Stronger H1 with TDAPA support before H2 headwinds; Q2 should still benefit from catheter lock TDAPA pre-mid-year expiry. First test of transition-year phasing | Reward: upside risk to first-half consensus. Risk: tone on SMTG + ACA + 5008X cadence sets H2 setup |
| 3 | Calcimimetic / phosphate binder TDAPA lapping (mid-2026 cliff) | TDAPA period ends 2026; catheter-lock TDAPA expires mid-2026 | EUR 220M binder contribution in 2025 (vs initial EUR 50-100M guide); ~EUR 100M expected to persist (EUR 50M clinic + EUR 50M pharmacy) | Single biggest 2027 modeling uncertainty per CFO: 'we don't know what bundle payment will be in 2027 yet' |
| 4 | ACA subsidy expiry phasing | Through 2026 and into 2027 | ~EUR 50M sized for 2026; phasing 'starts showing up Q2-Q4 as enrollment data flows.' Mgmt declined to quantify 2027-28 step | Negative read for ALL providers exposed to exchange-coverage patients (DVA, US Renal Care, Satellite) |
| 5 | GLP-1 ESRD progression impact (multi-year) | Monitored 2026-2030 | Long-running bear thesis; consensus increasingly views near-term volume impact as small; cardio-protective effect may EXPAND prevalent pool via longevity. Mgmt cites GLP-1-treated ESRD cohort as TAILWIND to 2%+ SMTG path | Reward: GLP-1 as tailwind, not headwind, per mgmt. Risk: structural long-term overhang if incidence pool compresses faster |
| 6 | FME25+ transformation completion | 2026 and 2027 | EUR 804M cumulative through 2025; EUR 400M incremental targeted 2026-27 for EUR 1.2B total; EUR 250M FY26 savings + EUR 350M FY26 onetime costs | Reward: Q1'26 EUR 50M ahead of pace; 64 of up to 100 US clinic closures already exited. Risk: 2026 dilutive on onetime costs |
| 7 | 5008X / HVHDF rollout — cohort maturation | FY26 deployment; mortality readout 2027+ | ~100 clinics + 100k+ treatments by early April; target 36,000 patients across 28 states. HVHDF mortality benefits ramp 2.5+ years post-3-month conversion | Reward: clinical + pricing differentiator vs DaVita; first cohort maturation visible 2027. Risk: costs front-loaded, benefits lag |
| 8 | Care Enablement portfolio (Joe Turk new CEO from Jan 1, 2026) | 2026-2027 | No formal divestiture; segment is core to FME Reignite. China VBP <EUR 50M 2026; consumables + 5008X ramp | Reward: new leadership + 5008X consumables ramp. Risk: chose to invest behind rather than divest = caps near-term value-unlock |
| 9 | Capital allocation / next buyback tranche | Likely H2 2026 / 2027 | Original EUR 1B program completed ~1 year ahead; 24.8M shares / 8.5% of capital. Net leverage 2.5x (low end of 2.5-3.0x band). Dividend EUR 1.49 +3% YoY | Reward: capacity for follow-on tranche. Risk: mgmt prioritizing 5008X capex + SAP S/4HANA before incremental return |
| 10 | VBC / CKCC contracting cycle | 2026 contracting cycle into 2027 | EUR 300M VBC FY26 revenue reduction from risk-contracting reset; expects earnings-neutral. VBC printed first full-year breakeven 2025 (EUR 3M OI vs EUR 28M loss 2024) | Reward: VBC inflects to positive low-SD margin contributor under 2030 framework. Risk: CKCC unfavorable adjustments hit Q4'25 OI |
| 11 | PY2027 Kt/V quality measure restructuring | CY2027 PPS rulemaking | Kt/V quality measure restructure proposed in CY2027 rulemaking — impacts QIP penalties | Risk: unfavorable quality measure changes compress 2027-28 economics |
| 12 | Vifor JV / pharmacy contribution + branded-to-generic erosion | Through 2026 | Renal Pharma JV with CSL Vifor continues to feed pharmacy contribution (~EUR 50M pharmacy binder retention). CEO Giza flagged 'we have to see how branded pricing erodes' | Risk: branded-to-generic erosion 2026/27 watch item |
Street Q&A
| # | Analyst (Firm) | Topic | Mgmt Response | Quality |
|---|---|---|---|---|
| — | CAVEAT | Q1'26 transcript unavailable via FMP | Q&A below from Quartr/StockAnalysis Q1'26 public summary + FY2025Q4 transcript context | Caveat |
| 1 | Doyle (UBS) | Post-TDAPA bridge to mid-teens margins | Pointed to FME25+ savings layer, HDF rollout efficiency benefits, RCM, US clinic closures, patient-safety/mortality work, underlying Care Delivery growth | Well Answered |
| 2 | Al-Wakeel (Barclays) | TDAPA quantification & SMTG -37 bps drivers | CFO Fischer: Q1 TDAPA ~EUR 80M cc. Giza: weather, missed treatments, ACA uncertainty, clinic closures, elevated mortality. Reaffirmed H1+/H2- phasing | Well Answered |
| 3 | Dubajova (Citi) | 5008X/HVHDF rollout pace + SMTG contingency | ~100 clinics, 100k+ treatments by early April; staff/patient feedback positive; mortality readout needs more time. Can trim capacity further if volumes stay soft | Well Answered |
| 4 | Solvet (BNPP) | Inflation envelope & ACA timing | Inflation tracking inside plan; ACA expected to materialize Q2-Q4; EUR 50M assumption held | Well Answered |
| 5 | Noor (Morgan Stanley) | China VBP & Value-Based Care | China is 7-10% of Care Enablement; ~half of expected 2026 China impact already absorbed in Q1; VBC tracking, no guidance revision | Well Answered |
| 6 | Ractliffe (BofA) | HDF cost cadence | Costs front-end loaded, linear to machine installs; benefits lag by quarters; framework unchanged from CMD | Well Answered |
| 7 | Vane-Tempest (Jefferies) | Operating cash flow / working capital | Confirmed FY bridge intact but did not fully unpack working-capital line; offered follow-up | Partially answered / deflected |
| 8 | Felton (Goldman Sachs) | China competitive dynamics | Market structurally attractive; local portfolio + GTM may need adjustment under VBP/tender regime; Joe Turk owns response | Well Answered |
| 9 | (Q1'26 notes) | Capital allocation status | Second EUR 415M tranche running Jan 12-May 8, 2026 completing EUR 1B program ~1 year ahead; net leverage 2.5x low end. Reinvestment in 5008X/SAP prioritized first | Well Answered |
| 10 | (Q1'26 notes) | Care Enablement future / divestiture? | No divestiture signaled; Joe Turk CE CEO Jan 1, 2026; segment core to FME Reignite with MSD revenue CAGR + industry-leading margin aspiration to 2030 | Well Answered |
| 11 | Pattern Observations | Where mgmt is strongest vs weakest | Strong: FME25+ math, TDAPA bridge mechanics. Recurring deflection: forward-period regulatory framing (ACA beyond 2026, phosphate binder bundle rate 2027). SMTG is most contested. Care Enablement divestiture not surfaced by analysts = Street accepts core under FME Reignite | — |
Contradictions
| # | Topic | Severity | Statement A | Statement B | Implication |
|---|---|---|---|---|---|
| 1 | US Same-Market Treatment Growth: '0.5%+' target vs delivered path | HIGH — multi-year pattern | Q1'25 (Giza): 'we continue to expect same market treatment growth of 0.5% plus for the U.S. in 2025... confident with our 0.5 plus for the year' | Q1'26: SMTG -37 bps; FY26 outlook 'carefully assume flat.' Walked down Q1'25 0.5%+ → Q2'25 'flat to slightly positive' → Q3 +0.1% → Q4 broadly flat → Q1'26 NEGATIVE | Multi-year pattern of overestimating US SMTG. The 2%+ 'normalized' anchor has become a permanent over-the-horizon ambition. Discount mgmt's volume-growth phasing in 2027-28 models. Weakens GLP-1 'supportive to ESRD survival' narrative because better mortality is what is supposed to deliver 2%+ |
| 2 | Care Enablement margin band: 'in the band, sustained' vs round-trip | HIGH — segment role reset | Q1'25 (Giza): 'our Care Enablement margin further improved to 8.3% for the first time it entered its target margin band of 8% to 12%... positioned for further growth and margin expansion beyond 2025' | Q4'25: Care Enablement earnings -6% on unfavorable China + currency transaction effects; sub-target margin profile. Margin slipped to 7.6% by Q3, Q4 revenue actually declined 3% on China | Care Enablement profitability more China- and FX-sensitive than Q1'25 framing suggested. Investors who took 'in the band, sustained' at face value got a six-quarter round trip. 2030 MSD CAGR + industry-leading margin aspiration depends on China stabilization that mgmt itself now acknowledges may require strategic change |
| 3 | Phosphate-binder/TDAPA contribution: 'EUR 50-100M' vs EUR 220M delivered | MEDIUM — positive miss creating taller cliff | Q1'25 (Fischer): 'we have outlined the full fiscal year effect' of approximately 'EUR 50M to EUR 100M operating income benefit' from phosphate binders for FY2025 | Q4'25 (Giza): 'Care Delivery performance was boosted by around EUR 40M higher-than-expected benefit from phosphate binders that fall into the TDAPA regulation, bringing it to around EUR 220M contribution in 2025.' (2x-4x initial guide) | Positive miss is still a forecasting miss — and creates a much taller TDAPA cliff. Once TDAPA fully expires 2027 the embedded base becomes harder to defend. Q1'26 confirms H1+/H2- TDAPA phasing — exactly the cliff this miss created. Treat new TDAPA-style windfalls as non-recurring, not base |
| 4 | Capital return: 'more to come in June' vs accelerated EUR 1B buyback | LOW — credible follow-through | Q1'25 (Giza on buybacks): 'More to come in June on what we plan to do with that capital and how we deploy it to shareholders... focused on value creation' | Q4'25 (Giza): 'we not only initiated but accelerated a EUR 1 billion share buyback program' with EUR 586M repurchased in 2025 + additional EUR 414M tranche Jan 2026 — completed ~1 year ahead | Cleanest example of evolving guidance NOT contradiction. 'Wait for CMD' framing was credible forward signal. Capital-return commitments have been honored at upper end + faster cadence. This is the right place to anchor mgmt-credibility debate — operational guidance has slipped, but balance-sheet commitments have held |
| 5 | Adjusted vs reported framing: '10% cc growth' vs reported OI down | MEDIUM — presentation tension | Q1'26: '10% constant-currency operating income growth excluding special items' and continued 'operational progress' | Reported OI EUR 286M vs ex-SI EUR 467M = EUR 181M of special items, materially higher than Q1'25's EUR 126M. Specials accelerating even as savings realized | For a name where equity reaction has been poor despite mgmt confidence, persistent gap between '10% growth ex-items' and reported P&L erodes credibility. Track reported OI + special items in addition to adjusted print. Specials likely persist through 2026 (front-loaded FME25+) |
| 6 | What is NOT a contradiction | — | GLP-1 ESRD framing has consistently been 'potentially supportive to ESRD survival rather than immediately destructive to dialysis demand' — Q4'25 explicit inclusion in path to 2%+ is constructive but consistent | FME25 / FME25+ pace: started EUR 180M for 2025 → upgraded EUR 220M → delivered EUR 238M → extended to FME25+ EUR 400M/EUR 400M through 2027. Over-delivery and program extension, not reversal | 2030 mid-teens group margin aspiration unchanged from CMD. The 2026-2028 bridge (3-7% OI CAGR) was new at Q4'25 but additive not contradictory |
Indirect Read-Throughs
| Company / Topic | Relationship | Quote / Mention | Read-Through |
|---|---|---|---|
| DaVita (DVA) | US duopoly partner / direct competitor | Q1'25: 'cyber-attack on DaVita... we have seen, during the quarter, some benefit from additional patient referrals.' Q3'25: 'your key competitor, DaVita quantified the impact on EBIT next year, well, actually the next 3 years, if the subsidies aren't extended.' Q4'25: FMS contrasted broadly-flat 2026 SMTG with DaVita's expected slow start | FMS picked up referrals during DVA cyber event Q2'25 — one-time tailwind that fades. FMS framing of ACA/TDAPA/volume risk reads similar to DVA — industry conditions not company-specific. HDF is FMS's main competitive differentiator vs DVA 2026-2028 |
| Baxter / Vantive (BAX, Vantive-Carlyle) | Care Enablement competitor (PD/HHD) | Q1'25: 'any changes in the competitive dynamic... Baxter sale of Vantive to Carlyle?' Giza: 'we both participate in different parts of the market... significant market share in HHD. We are clearly number 2 in PD.' | Confirms PD remains a duopoly with Vantive #1, FMS #2. Vantive's Carlyle ownership hasn't visibly changed competitive intensity. Watch Vantive's HDF response as FMS rolls out 5008X |
| Outset Medical (OM) | Home dialysis competitor | Not explicitly named; FMS retains 'significant market share in HHD' | Negative — FMS positions in-center HDF as survival-benefit alternative to home, complicating Outset's clinical narrative |
| Novo Nordisk (NVO) / Lilly (LLY) | GLP-1 manufacturers | Q4'25 (Giza): 'benefits from ESRD patients using GLP-1 are supporting this path to 2-plus percent growth.' Earlier quarters: GLP-1 as mortality benefit | CONSTRUCTIVE — dialysis duopoly views GLP-1 as additive to volume recovery thesis, NOT structural threat. Supports continued aggressive GLP-1 prescribing in CKD/ESRD comorbid populations |
| Akebia / vadadustat (AKBA) | Anemia / phosphate-binder TDAPA partner | Not named directly. TDAPA mechanics + ASP + bundle-transition apply to AKBA's vadadustat economics | NEGATIVE — TDAPA period finite (Jan 2027 expiry); branded pricing erodes into bundle. 'We have to see how branded pricing erodes' = further ASP pressure |
| ProKidney (PROK) | Regenerative CKD therapy | Q2'25: 'wait for the ASN... we are not the experts on that, but you have to see how long it actually holds and how long it would improve the outcomes' | Mgmt not treating ProKidney as imminent volume threat. Longer-dated optionality / risk for dialysis volumes if/when therapy proves durable |
| Humacyte (HUMA) | Equity investment | Recurring 'negative/positive effects from remeasurement of our investment in Humacyte' in special items every quarter | Humacyte's stock-price volatility creates non-cash FMS P&L noise in special-items line. FMS continues to hold position |
| Interwell Health | VBC platform (majority-owned) | Q3'25: 'we took an important step forward by increasing and strengthening our ownership stake in our Value-Based Care asset Interwell Health' with EUR 312M invested in Q3 | VBC being internalized further. Other VBC participants (Strive Health, Somatus, Monogram Health) face a more vertically integrated #1 competitor |
| Change Healthcare / UnitedHealth (UNH) | Payer infrastructure | Q3'25: 'around EUR 400M in catch-up reimbursement following the Change Healthcare cyber incident' | Confirms 2024 Change Healthcare disruption created ~EUR 400M of timing-related cash flow noise for FMS, now annualized. Residual reputational / counterparty risk on payer-rail infrastructure |
| US Renal Care / Satellite Healthcare | Smaller US dialysis chains | Not named directly; FMS's commentary on US clinic closures + competitive referral capture relevant | Modestly negative for #3 and #4 chains — industry-wide volume pressure + FMS's HDF differentiation + RCM raise bar for sub-scale operators |
| SAP / S/4HANA | IT platform vendor | Q4'25: 'investments in our IT platforms such as the required transition to SAP S/4HANA, supporting harmonization and standardization of core business processes' | POSITIVE for SAP — large European industrials committed to S/4HANA migrations through 2026-27. Modestly negative for FMS near-term margin as part of corporate-cost step-up |
| CMS / ESRD PPS | Reimbursement regulator | Repeated commentary on bundle pricing, TDAPA periods, ETC model wind-down, CKCC data delays | ESRD regulation in flux — TDAPA expiry, ACA subsidy fate, CKCC data delays create earnings volatility 2026-27 for ANY provider tied to CMS programs |
| China VBP / Tendering | Care Enablement geography | Q1'26: '~half of expected 2026 China headwind' absorbed in Q1. Mgmt: portfolio + GTM may need adjustment | Negative across premium medtech suppliers into China (Baxter/Vantive, B. Braun, Nipro, Asahi Kasei Medical) |
| FX (EUR/USD 1.18 assumed) | Macro | Q1'26: continued translational + transactional pressure | Negative for European medtech with US-heavy revenue (Siemens Healthineers, Sartorius, Carl Zeiss Meditec, BAX/Vantive) |
| ACA subsidy expiry | Macro / policy | FY26 ~EUR 50M sized; phasing Q2-Q4. Extended tax credits' fate unresolved through 2026 | Negative for ALL US providers exposed to exchange-coverage patients (DVA, US Renal Care, Satellite, hospitals with high ACA-exchange exposure) |
Data sourced from Daloopa. Document search is currently in beta; transcript and filing snippets may vary.